C1q, Human, ELISA kit – 1 x 96 det. - HK356-01
Quantity
1 x 96 det.
Catalog #
HK356-01
756,00 €
Verwandte Produkte
C1q, a key player in the classical complement pathway, seamlessly bridges innate and adaptive immunity. As part of the C1 complex, along with C1r and C1s, it activates upon binding to antibody-antigen complexes. This vital function positions C1q as an essential mediator in immune response management. Beyond activation, C1q recognizes IgG or IgM antibodies, initiating classical pathway activation through critical conformational changes. Its ability to bind apoptotic cells enhances immune clearance, preventing overstimulation.
Predominantly produced by macrophages and dendritic cells, C1q is pivotal in maintaining host defense and preventing autoimmune diseases like systemic lupus erythematosus (SLE). C1q deficiencies, whether genetic or from anti-C1q antibodies, impair apoptotic cell clearance, heightening SLE risk. This correlation is evident in conditions like proliferative glomerulonephritis and SLE flares, where C1q levels are notably low. The C1QA gene polymorphism, associated with reduced C1q levels, highlights its integral role in immune regulation. C1q's significance extends to its diagnostic potential in understanding complex immune diseases, making it a vital biomarker in immunological research.
.
Predominantly produced by macrophages and dendritic cells, C1q is pivotal in maintaining host defense and preventing autoimmune diseases like systemic lupus erythematosus (SLE). C1q deficiencies, whether genetic or from anti-C1q antibodies, impair apoptotic cell clearance, heightening SLE risk. This correlation is evident in conditions like proliferative glomerulonephritis and SLE flares, where C1q levels are notably low. The C1QA gene polymorphism, associated with reduced C1q levels, highlights its integral role in immune regulation. C1q's significance extends to its diagnostic potential in understanding complex immune diseases, making it a vital biomarker in immunological research.
.
| Datasheet URL | https://www.hycultbiotech.com/wp-content/uploads/2022/06/HK356-1223.pdf |
|---|---|
| Quantity | 1x96det. |
| Quantity | 1 x 96 det. |
| Standard range | 7.8 – 500 ng/ml |
| Detection level | 7.8 ng/ml |
| Working volume | 100 µl/well |
| Species | human |
| Cross reactivity | Cynomolgus monkey - Yes, Mouse - Yes, Pig - No, Rat - Yes |
| Application | The human C1q ELISA kit is to be used for the in vitro quantitative determination of human C1q and Ig containing circulating immune complexes (CIC) in serum, plasma and bronchoalveolar lavage fluid (BALF) samples. |
| Principle | The human C1q ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours. The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are incubated in microtiter wells coated with antibodies recognizing human C1q. Biotinylated tracer antibody will bind to captured human C1q. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human C1q standards (log). The human C1q concentration of samples, which are run concurrently with the standards, can be determined from the standard curve. |
| Storage and stability | Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least six months. |
| Precautions | For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product. |
| References | 1. Fernandez-Arias C et al; Malaria inhibits surface expression of complement receptor 1 in monocytes/macrophages, causing decreased immune complex internalization. J Immunol 2013, 190: 7 2. Mook-Kanamori B et al; Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis. J Infect 2014, 68: 6 3. Brookes C et al; Development of a large scale human complement source for use in bacterial immunoassays. J Immunol Methods 2013, 31: 391 |
| Disease | Nephrology, Neurological disorders |
| Application assays: | The human C1q ELISA kit is to be used for the in vitro quantitative determination of human C1q and Ig containing circulating immune complexes (CIC) in serum, plasma and bronchoalveolar lavage fluid (BALF) samples. |
|---|---|
| Principle: | The human C1q ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours. The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are incubated in microtiter wells coated with antibodies recognizing human C1q. Biotinylated tracer antibody will bind to captured human C1q. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human C1q standards (log). The human C1q concentration of samples, which are run concurrently with the standards, can be determined from the standard curve. |
Diese Artikel könnten Ihnen eventuell auch gefallen!
